David Malkin

University of Toronto
Country flagCanada

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (28)

BACKGROUND Digital Health Tools (DHTs), including wearables and mobile apps, offer promising avenues for personalized care and real-time monitoring, but user engagement and clinical utility—especially in pediatric populations—remain unclear. Li-Fraumeni syndrome (LFS) is a genetic mutation in the TP53 tumor suppressor gene, predisposing individuals to cancer, requiring lifelong surveillance and associated psychological stress. OBJECTIVE We evaluated engagement with DHTs in a cancer genetics clinic for families affected by LFS and explored their utility for patients and clinicians. Our goal was to identify insights that could inform future integration of DHTs in chronic disease populations and contribute to research. METHODS We conducted an observational study (January-December 2022) involving patients with LFS and family members aged 5 years and older. Participants received an Empatica EmbracePlus smartwatch and a suite of self-report surveys assessing psychosocial well-being at varying frequencies (ie, daily, weekly, etc). We used survival analysis to characterize engagement over time across age, TP53 status, and previous cancer history. Generalized additive models were used to explore physiological patterns relative to cancer surveillance events. Semistructured interviews provided qualitative insight into user experiences and preferences. RESULTS We enrolled 9 children and 36 adults. Adults wore their smartwatches more often than children (mean 81%, SD 19% vs mean 56%, SD 26%; t 10 . 1 =2 . 72; P = . 02) and were engaged in the study for a longer duration (median retention 153, IQR 119-179; 95% CI 133-177 vs median 77, IQR 36-151; 95% CI 17-171 days; log-rank χ 2 1 =4 . 4; P = . 04). Daily wear time was similar between the 2 groups (mean 17.6, SD 3.1 hours vs mean 15.7, SD 2.9 hours; t 13 . 2 =1 . 70; P = . 11). There were no differences in survey engagement between adults and children, nor were there differences in engagement across TP53 status or previous cancer history. Children reported greater psychosocial burden, with more depressive symptoms (PHQ-9 [Patient Health Questionnaire-9] score mean 10.0, SD 5.2 vs mean 4.2, SD 4.4; t 7 . 8 =2 . 8; P = . 03), worse sleep (PROMIS SRI [patient-reported outcomes measurement information system sleep-related impairment] score mean 22.7, SD 5.9 vs mean 16.5, SD 5.5; t 8 . 1 = − 2 . 58 ; P = . 03), and increased frequency of stress (mean 36.3%, SD 19.9% vs mean 14.3%, SD 19.2%; t 8 . 3 = − 2 . 7; P = . 03) than adults. A suicide alert system was triggered in 5 participants (11%) and prompted timely clinical intervention. Generalized additive model analysis showed individualized yet consistent physiological patterns of stress associated with cancer surveillance. Qualitative feedback from participants identified perceived value in stress awareness, but highlighted challenges with device comfort, functionality, and personalization. CONCLUSIONS DHTs are feasible and can capture clinically meaningful psychological and physiological data in high-risk pediatric and family populations with LFS. They enable timely detection of distress and facilitate targeted interventions. Our findings can inform best practices for patient-centered DHT integration into clinical care, with relevance to pediatric oncology and broader digital health contexts. CLINICALTRIAL

Year:

2025

Consistency in drug response between patients and their cognate larval zebrafish and mouse PDX models. Evaluable response to therapy was compared for each patient and their cognate larval zebrafish PDX and mouse PDX models. Patient and mouse responses are indicated as OR criteria. Larval zebrafish PDX models are indicated as response (inhibition of cell growth), SD (cell number maintained), or PD (cell growth in the presence of drug). Maintained CR, CR, and PR for patient and mouse are considered equivalent to R (response) in the larval zebrafish model. The concordance of response for each model type with patient response is summarized in the legends on the right. ***For zccs373 (nonresponder to triple combination), mouse PDX responded to dual combination. MCR, maintained complete response; NT, not treated; zf, zebrafish.

Year:

2025

Larval zebrafish drug efficacy studies for patients with no available mouse PDX. A to C, Patient information, alongside larval zebrafish tumor cell numbers for each therapy for rhabdomyosarcoma zccs170 ( A ), gastrointestinal stromal tumor zccs15 ( B ), and Ewing sarcoma zccs276 ( C ). For larval zebrafish data, error bars represent mean ± SEM, each colored dot represents an individual larva, and a threshold is based on SEM of 1 dpi. Statistical analysis was conducted using a one-way ANOVA with the Dunnett multiple comparisons test, comparing the mean of each treatment group with control (4 dpi), P values: *, D, Representative image of a five microns sectioned control larval zebrafish xenograft for patient zccs170. Deep Red–labeled patient cells present in the YS 4 dpi and labeled with DAPI to confirm viability. White circle in the images point to zccs170 tumor cells. Images were taken with 10× and 20× magnification. The scale bar is 100 µm. dpi, days post-injection.

Year:

2025

Mouse and larval zebrafish PDX drug efficacy for nonresponsive patients. A to C, Patient information, alongside mouse PDX waterfall plot of maximum tumor regression, and larval zebrafish tumor cell numbers for each therapy for neuroblastoma zccs373 ( A ), sarcoma zccs262 ( B ), and osteosarcoma zccs43 ( C ). For mouse PDX data, colored columns represent individual mice. For larval zebrafish data, error bars represent mean ± SEM, each colored dot represents an individual larva, and a threshold is based on SEM of 1 dpi. Statistical analysis was conducted using a one-way ANOVA with the Dunnett multiple comparisons test, comparing the mean of each treatment group with control (4 dpi), P values: *,

Year:

2025

Despite advances in precision medicine, 30% of high-risk pediatric cancers lack an actionable molecular target, hindering effective treatment and affecting survival outcomes. Although mouse patient-derived xenograft (PDX) models offer additional insights into clinical drug responses, delivering findings from these models within a clinically actionable time frame remains challenging. This international collaboration between two national precision medicine programs demonstrates proof-of-principle that individualized larval zebrafish PDXs can robustly and rapidly assess clinical responses in high-risk pediatric cancers. Retrospective zebrafish PDX testing was performed on tumor samples from 10 pediatric patients with high-risk cancers. Drug responses in zebrafish models were correlated with clinical responses for each patient and directly compared with responses in cognate mouse PDX models. Responses to conventional and targeted therapies, administered as single agents or in combinations, were assessed. Zebrafish PDXs were successfully established from all 10 patients and provided robust drug response data in every case, including from three patients whose tumor samples could not be engrafted in mice. Remarkably, zebrafish models accurately recapitulated patient responses for 11 of 12 treatment regimens. These findings highlight the potential of larval zebrafish PDX models to provide real-time, clinically relevant drug response data, supporting their potential use in prospective precision medicine studies. Significance: This proof-of-principle study is the first to compare drug responses in larval zebrafish and mouse PDX models with patient outcomes in pediatric precision oncology, showing high concordance. Results highlight the potential of zebrafish PDX models to predict drug responses in high-risk cancers more accurately, rapidly, and cost-effectively in prospective studies.

Year:

2025

Mouse and larval zebrafish PDX drug efficacy for responsive patients. A to D, Patient information, alongside mouse PDX waterfall plot of maximum tumor regression, and larval zebrafish tumor cell numbers for each therapy for Ewing sarcoma zccs505 ( A ), anaplastic large cell lymphoma zccs250 ( B ), neuroblastoma zccs51 ( C ), and Ewing sarcoma zccs59 ( D ). For mouse PDX data, colored columns represent individual mice. For larval zebrafish data, error bars represent mean ± SEM, each colored dot represents an individual larva, and a threshold is based on SEM of 1 dpi. Statistical analysis was conducted using a one-way ANOVA with the Dunnett multiple comparisons test, comparing the mean of each treatment group with control (4 dpi), P values: *,

Year:

2025

Background Wearable digital health technologies and mobile apps (personal digital health technologies [DHTs]) hold great promise for transforming health research and care. However, engagement in personal DHT research is poor. Objective The objective of this paper is to describe how participant engagement techniques and different study designs affect participant adherence, retention, and overall engagement in research involving personal DHTs. Methods Quantitative and qualitative analysis of engagement factors are reported across 6 unique personal DHT research studies that adopted aspects of a participant-centric design. Study populations included (1) frontline health care workers; (2) a conception, pregnant, and postpartum population; (3) individuals with Crohn disease; (4) individuals with pancreatic cancer; (5) individuals with central nervous system tumors; and (6) families with a Li-Fraumeni syndrome affected member. All included studies involved the use of a study smartphone app that collected both daily and intermittent passive and active tasks, as well as using multiple wearable devices including smartwatches, smart rings, and smart scales. All studies included a variety of participant-centric engagement strategies centered on working with participants as co-designers and regular check-in phone calls to provide support over study participation. Overall retention, probability of staying in the study, and median adherence to study activities are reported. Results The median proportion of participants retained in the study across the 6 studies was 77.2% (IQR 72.6%-88%). The probability of staying in the study stayed above 80% for all studies during the first month of study participation and stayed above 50% for the entire active study period across all studies. Median adherence to study activities varied by study population. Severely ill cancer populations and postpartum mothers showed the lowest adherence to personal DHT research tasks, largely the result of physical, mental, and situational barriers. Except for the cancer and postpartum populations, median adherences for the Oura smart ring, Garmin, and Apple smartwatches were over 80% and 90%, respectively. Median adherence to the scheduled check-in calls was high across all but one cohort (50%, IQR 20%-75%: low-engagement cohort). Median adherence to study-related activities in this low-engagement cohort was lower than in all other included studies. Conclusions Participant-centric engagement strategies aid in participant retention and maintain good adherence in some populations. Primary barriers to engagement were participant burden (task fatigue and inconvenience), physical, mental, and situational barriers (unable to complete tasks), and low perceived benefit (lack of understanding of the value of personal DHTs). More population-specific tailoring of personal DHT designs is needed so that these new tools can be perceived as personally valuable to the end user.

Year:

2024

The p53 tumor suppressor, encoded by the TP53 gene, serves as a major barrier against malignant transformation. Patients with Li-Fraumeni syndrome (LFS) inherit a mutated TP53 allele from one parent and a wild-type TP53 allele from the other. Subsequently, the wild-type allele is lost and only the mutant TP53 allele remains. This process, which is termed loss of heterozygosity (LOH), results in only mutant p53 protein expression. We used primary dermal fibroblasts from LFS patients carrying the hotspot p53 gain-of-function pathogenic variant, R248Q to study the LOH process and characterize alterations in various pathways before and after LOH. We previously described the derivation of mutant p53 reactivating peptides, designated pCAPs (p53 Conformation Activating Peptides). In this study, we tested the effect of lead peptide pCAP-250 on LOH and on its associated cellular changes. We report that treatment of LFS fibroblasts with pCAP-250 prevents the accumulation of mutant p53 protein, inhibits LOH, and alleviates its cellular consequences. Furthermore, prolonged treatment with pCAP-250 significantly reduces DNA damage and restores long-term genomic stability. pCAPs may thus be contemplated as a potential preventive treatment to prevent or delay early onset cancer in carriers of mutant p53.

Year:

2024

BACKGROUND Wearable digital health technologies and mobile apps (personal digital health technologies [DHTs]) hold great promise for transforming health research and care. However, engagement in personal DHT research is poor. OBJECTIVE The objective of this paper is to describe how participant engagement techniques and different study designs affect participant adherence, retention, and overall engagement in research involving personal DHTs. METHODS Quantitative and qualitative analysis of engagement factors are reported across 6 unique personal DHT research studies that adopted aspects of a participant-centric design. Study populations included (1) frontline health care workers; (2) a conception, pregnant, and postpartum population; (3) individuals with Crohn disease; (4) individuals with pancreatic cancer; (5) individuals with central nervous system tumors; and (6) families with a Li-Fraumeni syndrome affected member. All included studies involved the use of a study smartphone app that collected both daily and intermittent passive and active tasks, as well as using multiple wearable devices including smartwatches, smart rings, and smart scales. All studies included a variety of participant-centric engagement strategies centered on working with participants as co-designers and regular check-in phone calls to provide support over study participation. Overall retention, probability of staying in the study, and median adherence to study activities are reported. RESULTS The median proportion of participants retained in the study across the 6 studies was 77.2% (IQR 72.6%-88%). The probability of staying in the study stayed above 80% for all studies during the first month of study participation and stayed above 50% for the entire active study period across all studies. Median adherence to study activities varied by study population. Severely ill cancer populations and postpartum mothers showed the lowest adherence to personal DHT research tasks, largely the result of physical, mental, and situational barriers. Except for the cancer and postpartum populations, median adherences for the Oura smart ring, Garmin, and Apple smartwatches were over 80% and 90%, respectively. Median adherence to the scheduled check-in calls was high across all but one cohort (50%, IQR 20%-75%: low-engagement cohort). Median adherence to study-related activities in this low-engagement cohort was lower than in all other included studies. CONCLUSIONS Participant-centric engagement strategies aid in participant retention and maintain good adherence in some populations. Primary barriers to engagement were participant burden (task fatigue and inconvenience), physical, mental, and situational barriers (unable to complete tasks), and low perceived benefit (lack of understanding of the value of personal DHTs). More population-specific tailoring of personal DHT designs is needed so that these new tools can be perceived as personally valuable to the end user.

Year:

2024

Genomic features of patients with RRD-HGG treated with salvage therapies ( n = 38). A, Onco-plot summarizing clinical and genomic features of patients who progressed on anti–PD-1 monotherapy and continued ICI treatment. B, Impact of TMB on survival. C, Impact of genomic MSI as measured by the tumor MMRDness score on survival (Methods).

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (37)

Daniel A. Morgenstern

Royal Marsden NHS Foundation Trust

UNITED KINGDOM
View details

Raymond H. Kim

Associate Professor

University Health Network

CANADA
View details

Ryuma Tanaka

Assistant Professor

Nationwide Children's Hospital

UNITED STATES
View details

Derek S. Tsang

Staff Radiation Oncologist

-

CANADA
View details

Uri Tabori

Section Head of Neuro-Oncology

Hospital for Sick Children

CANADA
View details

David Ziegler

Professor

University of New South Wales

AUSTRALIA
View details

Wei Xu

University of Toronto

CANADA
View details

Gabor Tax

Children's Cancer Institute Australia

AUSTRALIA
View details

Kara Maxwell

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Adam Shlien

Wellcome Sanger Institute

UNITED KINGDOM
View details

Daniel Karlin

Assistant Professor

Tufts University School of Medicine

UNITED STATES
View details

Jennifer Chan

Broad Institute

UNITED STATES
View details

Chetan Bettegowda

Johns Hopkins University School of Medicine

UNITED STATES
View details

Anita Villani

Hospital for Sick Children

CANADA
View details

Andrea S. Doria

Hospital for Sick Children

CANADA
View details

Ute Bartels

University of Toronto

CANADA
View details

Kim Erika Nichols

Full Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Carl Koschmann

University of Michigan Medical School

UNITED STATES
View details

Robert C. Grant

University Health Network

CANADA
View details

Michal Zapotocky

University Hospital in Motol

CZECH REPUBLIC
View details

Gad Getz

Broad Institute

UNITED STATES
View details

Alvin Kamili

Children's Cancer Institute Australia

AUSTRALIA
View details

Matthias Holdhoff

Johns Hopkins University School of Medicine

UNITED STATES
View details

Pierre Hainaut

Professor, Cancer Biology. Director, IAB

Université Grenoble Alpes

FRANCE
View details

Eric Bouffet

Neuro-Oncologist

Hospital for Sick Children

CANADA
View details

Birgit Ertl-Wagner

Radiologist-in-Chief

Hospital for Sick Children

CANADA
View details

Simon P L Travis

University of Oxford

UNITED KINGDOM
View details

Vijay Ramaswamy

Associate Professor

University of Toronto

CANADA
View details

Trevor J. Pugh

Professor

University Health Network

CANADA
View details

Anirban Das

Hospital for Sick Children

CANADA
View details

Jamie Fletcher

Conjoint Associate Professor

University of New South Wales

AUSTRALIA
View details

Stephen Friend

Senior Scientist/ International Scholar

Hospital for Sick Children

CANADA
View details

Peter B. Dirks

-

CANADA
View details

Yosef Maruvka

Assistant professor

Technion - Israel Institute of Technology

ISRAEL
View details

Donna Senger

Professor

McGill University

CANADA
View details

Jason N. Berman

Children's Hospital of Eastern Ontario

CANADA
View details

Ping Luo

Assistant Professor

Algoma University

CANADA
View details